Co-Diagnostics Opens New Facility in South Salt Lake
April 11, 2024
Co-Diagnostics (Co-Dx) yesterday held a ribbon-cutting ceremony to celebrate the grand opening of the company’s new manufacturing facility, located at 3222 S. Washington St. in South Salt Lake.
South Salt Lake Mayor Cherie Wood, Lance Soffe and Jim Grover with the Governor’s Office of Economic Opportunity, David Carlebach with World Trade Center Utah, representatives from the offices of U.S. Senators Mike Lee and Mitt Romney, and U.S. Representatives John Curtis and Celeste Maloy, BioUtah CEO, Kelvyn Cullimore, employees, Kirk Ririe founder of Biofire, and other dignitaries were on hand to recognize the day.
The facility will create an additional 400 jobs and bring quality PCR (molecular) testing to homes and point-of-care settings. Co-Dx CEO, Dwight Egan, thanked his team who he said has been working late nights to deliver accessible, affordable, “gold standard” PCR testing for all with its innovative Co-Dx PCR™ testing platform. The platform will provide results in about 30 minutes for COVID-19, influenza, RSV, tuberculosis and HPV.
Mark Welcker, director of business outreach for Senator Lee, shared a prepared statement, which in part read, “Senator Lee extends his warmest congratulations to the entire Co-Diagnostics team. Your efforts are truly making a difference in patients’ lives, and you are playing a pivotal role in powering our state’s economy through innovation and excellence. Thank you for your dedication to advancing medical technology and for your contribution to our community.”
Addressing attendees, Cullimore noted that Utah has one of the highest concentrations of life sciences employment in the country. “It is innovative companies like Co-Diagnostics that are driving job growth in the state.” he said.
Today’s event included a special tour of the new facility. Guests learned about the build out to come, the testing technology – similar to the size and shape of a small box of tissue – and observed workers engaged in production.
Recent News
- Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology
- PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
- Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
- Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™
- Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5